<DOC>
	<DOCNO>NCT01131702</DOCNO>
	<brief_summary>The purpose study compare rate extent absorption ranitidine 300 mg tablet versus Zantac 300 mg tablet administer 1 x 300 mg tablet fast condition .</brief_summary>
	<brief_title>Bioequivalency Study Ranitidine Tablets 300 mg Dr. Reddy 's Under Fasting Conditions</brief_title>
	<detailed_description>This study compare rate extent absorption ranitidine 300 rng tablet versus Zantac . The study product administer single oral dose 1 x 300 mg tablet use randomize , two-way crossover fast study non-smoker healthy volunteer washout period 7 day .</detailed_description>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<criteria>Subjects enrol study member community large . The recruitment advertisement may do use different medium ( e.g . radio , newspaper , Anapharm Inc . Web site . Anapharm Inc. volunteer ' data base ) . Subjects must meet follow criterion order include study : Subjects females and/or male , nonsmoker , 18 year age old . Subjects follow applies exclude study : Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical sub investigator would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg ; heart rate less 50 100 bpm ) screening . Subjects BMI â‰¥ 30.0 . History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History ofdrug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . History allergic reaction ranitidine Hr receptor antagonist ( e.g.cimetidine , famotidine , nizatidine ) . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate . carbamazepine . phenytoin . glucocorticoid rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin ketoconazole , MAO inhibitor , neuroleptic , verapamil . quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . History presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea inflammatory bowel disease ) unresolved gastrointestinal symptom ( e.g.diarrhea , vomit ) , liver kidney disease condition know interfere absorption , distribution , metabolism excretion drug . Any history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Use tobacco product last 6 month . Any food allergy , intolerance , restriction special diet , opinion medical sub investigator , contraindicate subject 's participation study . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : less 300 niL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . Subjects history know presence porphyria . Additional exclusion criterion female : Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) . Female subject childbearing potential unprotected sexual intercourse nonsterile male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . The acceptable method contraception : Condom + spermicide Diaphragm +spermicide Intrauterine contraceptive device ( place least 4 week prior study drug administration ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Crossover</keyword>
	<keyword>Ranitidine</keyword>
</DOC>